In 2018, another randomized controlled study (NCT03118128) by Christian et al. showed that for ALL patients with high ABCB1 expression, metformin combined with the LALHGM07 chemotherapy regimen improved survival and reduced the risk of treatment failure (OR = 0.07, 95% CI = 0.0037–1.53) and early recurrence (OR = 0.05, 95% CI = 0.0028–1.153). Here, ABCB1 is linked to acute lymphoblastic leukemia.